{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:47Z","timestamp":1792782707917,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Essen","id":[{"id":"https:\/\/ror.org\/02na8dn90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln (\u201emedication overuse headache\u201c [MOH]) treten h\u00e4ufig bei Patienten mit chronischer Migr\u00e4ne auf und sind gekennzeichnet durch eine Verschlechterung der Migr\u00e4ne bei gleichzeitig zunehmender Verwendung von Akutmedikation. Chronische Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln sind ein relevantes Problem in der klinischen Praxis und die aktuelle Leitlinie empfiehlt, dass Patienten durch eine Edukation angeleitet werden sollen, ihren Medikamenten\u00fcbergebrauch zu reduzieren.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel<\/jats:title>\n                    <jats:p>Ziel war es, zu untersuchen, welche publizierten Ans\u00e4tze zur Edukation bei chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln vorliegen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>Es wurde eine systematische Literaturrecherche in PubMed durchgef\u00fchrt. Eingeschlossen wurden Publikationen, in denen inhaltliche Details zu Edukationen bei chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln aufgef\u00fchrt sind. Die beschriebenen Edukationsans\u00e4tze wurden thematisch analysiert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Es wurden 12\u00a0Publikationen eingeschlossen. Die beschriebenen Edukationsma\u00dfnahmen waren wirksam zur Reduktion oder Pr\u00e4vention von Medikamenten\u00fcbergebrauch oder chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln. Die Edukationsinhalte sind heterogen, wobei bestimmte Kernthemen in den meisten Edukationsans\u00e4tzen enthalten sind. Diese lassen sich den Themenfeldern \u201eGrundlagen zum Konzept Medikamenten\u00fcbergebrauch oder chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln\u201c, \u201eRisikofaktoren\u201c und \u201eTherapieoptionen\u201c zuordnen. In wenigen Publikationen fanden sich zus\u00e4tzlich inhaltliche Schwerpunkte, die sich dem Themenfeld \u201eAbsprache von Behandlungszielen\u201c zuordnen lassen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerungen<\/jats:title>\n                    <jats:p>Edukation ist wirksam bei der Pr\u00e4vention und Behandlung von Patienten mit Medikamenten\u00fcbergebrauch oder chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln, wird aber uneinheitlich umgesetzt. Die hier pr\u00e4sentierte \u00dcbersicht kann als Grundlage f\u00fcr einen strukturierten Edukationsansatz f\u00fcr die Behandlung von chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln dienen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00482-025-00891-9","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:08:35Z","timestamp":1750234115000},"page":"354-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Edukation bei chronischen Kopfschmerzen durch \u00dcbergebrauch von Schmerz- und Migr\u00e4nemitteln","Education for medication overuse headache"],"prefix":"10.1007","volume":"40","author":[{"given":"Hans-Christoph","family":"Diener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"L\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina\u00a0S, Terwindt\u00a0GM, Steiner\u00a0TJ et\u00a0al (2023) Medication overuse headache. Nat Rev Dis Primers 9:5","journal-title":"Nat Rev Dis Primers"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1177\/0333102417736898","volume":"38","author":"LN Carlsen","year":"2018","unstructured":"Carlsen\u00a0LN, Westergaard\u00a0ML, Bisgaard\u00a0M et\u00a0al (2018) National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 38:1316\u20131325","journal-title":"Cephalalgia"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ene.14268","volume":"27","author":"HC Diener","year":"2020","unstructured":"Diener\u00a0HC, Antonaci\u00a0F, Braschinsky\u00a0M et\u00a0al (2020) European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol 27:1102\u20131116","journal-title":"Eur J Neurol"},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42466-022-00200-0","volume":"4","author":"HC Diener","year":"2022","unstructured":"Diener\u00a0HC, Kropp\u00a0P, Dresler\u00a0T et\u00a0al (2022) Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract 4:37","journal-title":"Neurol Res Pract"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pain.2010.07.032","volume":"151","author":"G Fritsche","year":"2010","unstructured":"Fritsche\u00a0G, Frettloh\u00a0J, Huppe\u00a0M et\u00a0al (2010) Prevention of medication overuse in patients with migraine. Pain 151:404\u2013413","journal-title":"Pain"},{"key":"891_CR6","volume-title":"International Classification of Headache Diseases","author":"International Headache Society","year":"2021","unstructured":"International Headache Society (2021) International Classification of Headache Diseases, 3.\u00a0Aufl.","edition":"3"},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"1114654","DOI":"10.3389\/fneur.2023.1114654","volume":"14","author":"RH Jensen","year":"2023","unstructured":"Jensen\u00a0RH, Schytz\u00a0HW, Tassorelli\u00a0C et\u00a0al (2023) Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION\u2011A phase\u00a04, multinational, randomized, double-blind, placebo-controlled study. Front Neurol 14:1114654","journal-title":"Front Neurol"},{"key":"891_CR8","doi-asserted-by":"crossref","unstructured":"Klan T, Diezemann-Pr\u00f6\u00dfdorf A, Guth A\u2011L et\u00a0al (2023) Attackenangst bei Migr\u00e4ne: Diagnostik und Behandlung. Schmerz: 1\u20138","DOI":"10.1007\/s00482-023-00711-y"},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2377-12-70","volume":"12","author":"ES Kristoffersen","year":"2012","unstructured":"Kristoffersen\u00a0ES, Straand\u00a0J, Benth\u00a0JS et\u00a0al (2012) Study protocol: Brief intervention for medication overuse headache\u2014A double-blinded cluster randomised parallel controlled trial in primary care. BMC Neurol 12:70","journal-title":"BMC Neurol"},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/ene.13318","volume":"24","author":"ES Kristoffersen","year":"2017","unstructured":"Kristoffersen\u00a0ES, Straand\u00a0J, Russell\u00a0MB et\u00a0al (2017) Lasting improvement of medication-overuse headache after brief intervention\u2014a\u00a0long-term follow-up in primary care. Eur J Neurol 24:883\u2013891","journal-title":"Eur J Neurol"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/jnnp-2014-308548","volume":"86","author":"ES Kristoffersen","year":"2015","unstructured":"Kristoffersen\u00a0ES, Straand\u00a0J, Vetvik\u00a0KG et\u00a0al (2015) Brief intervention for medication-overuse headache in primary care. The BIMOH study: a\u00a0double-blind pragmatic cluster randomised parallel controlled trial. J\u00a0Neurol Neurosurg Psychiatry 86:505\u2013512","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s15006-015-2651-z","volume":"157","author":"P Kropp","year":"2015","unstructured":"Kropp\u00a0P, Klinger\u00a0R, Dresler\u00a0T (2015) Schmerztagebuch, Wochenende, Schokolade und Rotwein. Die Erwartungshaltung \u2013 Migraneausl\u00f6ser Nummer\u00a01? MMW Fortschr Med 157:62\u201364","journal-title":"MMW Fortschr Med"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00482-017-0214-1","volume":"31","author":"P Kropp","year":"2017","unstructured":"Kropp\u00a0P, Meyer\u00a0B, Dresler\u00a0T et\u00a0al (2017) Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migr\u00e4ne: Leitlinie der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft. Schmerz 31:433\u2013447","journal-title":"Schmerz"},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/head.13194","volume":"58","author":"AM Lagman-Bartolome","year":"2018","unstructured":"Lagman-Bartolome\u00a0AM, Lawler\u00a0V, Lay\u00a0C (2018) Headache Education Active-Waiting Directive: A\u00a0Program to Enhance Well-Being During Long Referral Wait Times. Headache 58:109\u2013117","journal-title":"Headache"},{"issue":"3","key":"891_CR15","first-page":"88","volume":"46","author":"AE Lake 3rd","year":"2006","unstructured":"Lake\u00a0AE 3rd (2006) Medication overuse headache: biobehavioral issues and solutions. Headache 46(3):88\u201397","journal-title":"Headache"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton\u00a0RB, Buse\u00a0DC, Nahas\u00a0SJ et\u00a0al (2023) Risk factors for migraine disease progression: a\u00a0narrative review for a\u00a0patient-centered approach. J\u00a0Neurol 270:5692\u20135710","journal-title":"J Neurol"},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1080\/09638288.2018.1526337","volume":"42","author":"A Mclean","year":"2020","unstructured":"Mclean\u00a0A, Becker\u00a0WJ, Vujadinovic\u00a0Z (2020) Making a\u00a0new-patient headache education session more patient-centered: what participants want to know. Disabil Rehabil 42:1462\u20131473","journal-title":"Disabil Rehabil"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s13760-021-01758-3","volume":"121","author":"AL Moraes Alves","year":"2021","unstructured":"Moraes Alves\u00a0AL, Silva\u00a0IK, Lemos\u00a0PPH et\u00a0al (2021) FRAMES protocol versus simple advice for medication-overuse headache: a\u00a0prospective, randomized, controlled clinical trial. Acta Neurol Belg 121:1259\u20131264","journal-title":"Acta Neurol Belg"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"237437352110342","DOI":"10.1177\/23743735211034289","volume":"8","author":"LS Mose","year":"2021","unstructured":"Mose\u00a0LS, Bornhoft\u00a0JO, Primdahl\u00a0J et\u00a0al (2021) Coping and Motivation for Change\u2014An Interview Study of the Experience From Participation in an Educational Program for Patients With Medication-Overuse Headache. J\u00a0Patient Exp 8:23743735211034289","journal-title":"J Patient Exp"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ejp.1500","volume":"24","author":"LS Mose","year":"2020","unstructured":"Mose\u00a0LS, Pedersen\u00a0SS, Jensen\u00a0RH et\u00a0al (2020) Medication-overuse headache: The effect of a\u00a0patient educational programme\u2011A randomized controlled trial. Eur J Pain 24:435\u2013447","journal-title":"Eur J Pain"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11916-015-0500-5","volume":"19","author":"DB Penzien","year":"2015","unstructured":"Penzien\u00a0DB, Irby\u00a0MB, Smitherman\u00a0TA et\u00a0al (2015) Well-Established and Empirically Supported Behavioral Treatments for Migraine. Curr Pain Headache Rep 19:34","journal-title":"Curr Pain Headache Rep"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/ene.15256","volume":"29","author":"JA Pijpers","year":"2022","unstructured":"Pijpers\u00a0JA, Kies\u00a0DA, Van Zwet\u00a0EW et\u00a0al (2022) Behavioural intervention in medication overuse headache: A\u00a0concealed double-blind randomized controlled trial. Eur J Neurol 29:1496\u20131504","journal-title":"Eur J Neurol"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1468-2982.2006.01175.x","volume":"26","author":"P Rossi","year":"2006","unstructured":"Rossi\u00a0P, Di Lorenzo\u00a0C, Faroni\u00a0J et\u00a0al (2006) Advice alone vs. structured detoxification programmes for medication overuse headache: a\u00a0prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 26:1097\u20131105","journal-title":"Cephalalgia"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner\u00a0TJ, Jensen\u00a0R, Katsarava\u00a0Z et\u00a0al (2019) Aids to management of headache disorders in primary care (2nd\u00a0edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J\u00a0Headache Pain 20:57","journal-title":"J Headache Pain"},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jamaneurol.2024.3043","volume":"81","author":"SJ Tepper","year":"2024","unstructured":"Tepper\u00a0SJ, Dodick\u00a0DW, Lanteri-Minet\u00a0M et\u00a0al (2024) Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A\u00a0Phase\u00a04, Randomized, Placebo-Controlled Trial. JAMA Neurol 81:1140\u20131149","journal-title":"JAMA Neurol"},{"key":"891_CR26","volume-title":"Primary care management of headache in adults: clinical practice guideline","author":"Toward Optimized Practice (Top) Headache Working Group","year":"2016","unstructured":"Toward Optimized Practice (Top) Headache Working Group (2016) Primary care management of headache in adults: clinical practice guideline, 2.\u00a0Aufl. Toward Optimized Practice, Edmonton AB","edition":"2"},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12883-024-03586-3","volume":"24","author":"FE Ucan Tokuc","year":"2024","unstructured":"Ucan Tokuc\u00a0FE, Goksu\u00a0EO, Kati\u00a0SD (2024) Internal stigmatization in patients with chronic migraine and medication overuse headache. BMC Neurol 24:100","journal-title":"BMC Neurol"},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102419883355","volume":"40","author":"J Xu","year":"2020","unstructured":"Xu\u00a0J, Kong\u00a0F, Buse\u00a0DC (2020) Predictors of episodic migraine transformation to chronic migraine: A\u00a0systematic review and meta-analysis of observational cohort studies. Cephalalgia 40:503\u2013516","journal-title":"Cephalalgia"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-025-00891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-025-00891-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-025-00891-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:03:41Z","timestamp":1790100221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-025-00891-9"}},"subtitle":["Ergebnisse einer systematischen Literaturrecherche","Results of a\u00a0systematic literature review"],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s00482-025-00891-9","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"15 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Graf: Mitarbeiterin Lundbeck GmbH. H.\u00a0L\u00f6hr: Mitarbeiter Lundbeck GmbH. P.\u00a0Kropp und H.-C.\u00a0Diener erkl\u00e4ren, dass sie die folgenden finanziellen Zuwendungen f\u00fcr Forschungsprojekte, Beratungst\u00e4tigkeiten oder Vortragshonorare der folgenden Institutionen und Firmen erhalten haben: P.\u00a0Kropp: DFG, BMBF, GbA, Allergan, Lilly, Lundbeck, Novartis, TEVA. H.-C.\u00a0Diener: DFG, BMBF, Ipsen, Lilly, Lundbeck, Medscape, WebMD.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}